Literature DB >> 10439805

CD30 expression is common in mediastinal large B-cell lymphoma.

J P Higgins1, R A Warnke.   

Abstract

Large B-cell lymphoma manifesting in the mediastinum shows distinctive clinical and immunophenotypic features and is recognized as a unique type of large B-cell lymphoma in the Revised European-American Lymphoma classification. Fifty-one cases of primary mediastinal large B-cell lymphoma were retrieved from the immunodiagnosis laboratory database files and were stained with anti-CD30 (Ber-H2). Of the 51 cases, 35 (69%) stained for CD30. This staining ranged from strong membrane staining of all or almost all of the neoplastic cells to positivity of rare individual cells. Eleven cases (22%) were negative; 4 (8%) were equivocal. Only 1 case was uninterpretable owing to B-5 fixation and lack of a positive internal control. Thus, the majority of mediastinal large B-cell lymphomas express the Hodgkin marker CD30. This finding may result in misdiagnosis of large cell lymphoma as Hodgkin disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10439805     DOI: 10.1093/ajcp/112.2.241

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  26 in total

1.  Gene expression in the normal adult human kidney assessed by complementary DNA microarray.

Authors:  John P T Higgins; Lingli Wang; Neeraja Kambham; Kelli Montgomery; Veronica Mason; Stefanie U Vogelmann; Kevin V Lemley; Patrick O Brown; James D Brooks; Matt van de Rijn
Journal:  Mol Biol Cell       Date:  2003-12-02       Impact factor: 4.138

2.  Primary mediastinal large B-cell lymphoma: a single-center study of clinicopathologic characteristics.

Authors:  Slobodanka Ostojić Kolonić; Sonja Dzebro; Rajko Kusec; Ana Planinc-Peraica; Mara Dominis; Branimir Jaksić
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 3.  Primary mediastinal DLBCL: evolving biologic understanding and therapeutic strategies.

Authors:  Pier Luigi Zinzani; Pier Paolo Piccaluga
Journal:  Curr Oncol Rep       Date:  2011-10       Impact factor: 5.075

Review 4.  Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results.

Authors:  Scott D Boyd; Yasodha Natkunam; John R Allen; Roger A Warnke
Journal:  Appl Immunohistochem Mol Morphol       Date:  2013-03

5.  [Mediastinal large B-cell lymphoma].

Authors:  T F E Barth; P Möller
Journal:  Pathologe       Date:  2007-02       Impact factor: 1.011

6.  Primary mediastinal large B-cell lymphoma: a comparative study with nodular sclerosis-type Hodgkin's disease.

Authors:  N Yonetani; M Kurata; M Nishikori; H Haga; K Ohmori; H Yamabe; T Uchiyama; H Ohno
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

7.  Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France.

Authors:  Leticia Quintanilla-Martinez; Daphne de Jong; Antoine de Mascarel; Eric D Hsi; Philip Kluin; Yaso Natkunam; Marie Parrens; Stefano Pileri; German Ott
Journal:  J Hematop       Date:  2009-12-22       Impact factor: 0.196

8.  Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1.

Authors:  Meili Zhang; Zhengsheng Yao; Hiral Patel; Kayhan Garmestani; Zhuo Zhang; Vladimir S Talanov; Paul S Plascjak; Carolyn K Goldman; John E Janik; Martin W Brechbiel; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-08       Impact factor: 11.205

Review 9.  Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma?

Authors:  Kieron Dunleavy; Cliona Grant; Franziska C Eberle; Stefania Pittaluga; Elaine S Jaffe; Wyndham H Wilson
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

10.  Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype.

Authors:  K Ameri; R Luong; H Zhang; A A Powell; K D Montgomery; I Espinosa; D M Bouley; A L Harris; S S Jeffrey
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.